Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer - Related Studies

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

This study is ongoing, but not recruiting participants.

Study NCT00002855. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Prostate Cancer

2	Additional conditions recognized in this trial
		Prostatic Neoplasms

3	More general conditions related to this trial
		Genital Diseases, Male
		Genital Neoplasms, Male
		Neoplasms
		Neoplasms by Site
		Prostatic Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		bicalutamide
		doxorubicin hydrochloride
		estramustine phosphate sodium
		flutamide
		ketoconazole
		nilutamide
		therapeutic hydrocortisone
		vinblastine
		conventional surgery
		endocrine drug therapy

5	Additional drug interventions recognized in this trial
		Cortisol succinate
		Doxorubicin
		Estramustine
		Hydrocortisone
		Hydrocortisone acetate

6	More general drug interventions related to this trial
		Alkylating Agents
		Androgen Antagonists
		Anti-Infective Agents
		Anti-Inflammatory Agents
		Antibiotics, Antineoplastic
		Antifungal Agents
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antineoplastic Agents, Hormonal
		Antineoplastic Agents, Phytogenic
		Hormone Antagonists
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses
		Tubulin Modulators

7	Sponsors listed in this trial
		M.D. Anderson Cancer Center
		National Cancer Institute (NCI)